The firm will use the proceeds to advance AIR-001 as its lead candidate and file a clinical trial application later this year.

The biomarker analysis found patients with certain mutations in the PI3K/AKT/mTOR pathway and MAPK pathway may be resistant to Truqap.

Patients on Adcetris and chemo had better progression-free and overall survival after six years of follow-up compared to those on chemo only.

The firm is evaluating its radiopharmaceutical imaging agent targeting PDGFRα, TLX300-CDx, in advanced or metastatic soft tissue sarcoma.

The firm will focus on programs for MYBPC3-associated hypertrophic cardiomyopathy and PKP2-associated arrhythmogenic right ventricular cardiomyopathy.

The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.

Patients at risk for heart disease experienced significant reductions in apolipoprotein B and LDL cholesterol levels on ...

HHS had argued that Vertex's plan to cover fertility services for some patients that took its gene therapy would violate anti-kickback and inducement laws.

The benefits of early TAVR for patients with asymptomatic, severe aortic stenosis are consistent regardless of NT-proBNP or ...

Researchers shared data at ACC from BioCardia's initial Phase III cell therapy trial, which the firm stopped enrolling based ...

NEW YORK – The National Comprehensive Cancer Network has taken a more favorable stance on DPYD pharmacogenetic testing in recently updated colon, anal, rectal, and small bowel cancer treatment ...

The firms hope to show that Verdi's off-the-shelf peptide cancer vaccine can shrink tumors and improve quality of life in patients with bone metastases.